Date: 27th July, 2024

To The Listing Department **National Stock Exchange of India Limited** Exchange Plaza, Bandra – Kurla Complex Bandra (East) Mumbai – 400 051 ***Stock Code : INDOCO-EQ***	To The Listing Department **Bombay Stock Exchange Limited** Floor 25, P. J. Towers, Dalal Street, Mumbai – 400 001 ***Stock Code :* 532612**

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that United States Food and Drug Administration (USFDA) had inspected Company's manufacturing facilities at Plant II (Sterile) and Plant III located at Goa ("**Facility**") from July 16, 2024 to July 26, 2024. On conclusion of the inspection, the Company received 7 (seven) observations in Form 483.

We are addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe.

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

RAMANATHAN HARIHARAN
Digitally signed by RAMANATHAN HARIHARAN
Date: 2024.07.27 14:53:26 +05'30'

Ramanathan Hariharan
Company Secretary & Head- Legal